Gender-Affirming Care

The execrable gender ideologue Admiral Rachel Levine is no longer in government. That’s great news in the long run for children with gender dysphoria, because the new administration wants to actually protect these disturbed minors. Accordingly, President Trump today signed an executive order protecting such children from being subjected to often irreparable body-altering “gender-affirming care.” From the order, “Protecting Children from Chemical and Surgical Mutilation:”

Across the country today, medical professionals are maiming and sterilizing a growing number of impressionable children under the radical and false claim that adults can change a child’s sex through a series of irreversible medical interventions. This dangerous trend will be a stain on our Nation’s history, and it must end.

Countless children soon regret that they have been mutilated and begin to grasp the horrifying tragedy that they will never be able to conceive children of their own or nurture their children through breastfeeding. Moreover, these vulnerable youths’ medical bills may rise throughout their lifetimes, as they are often trapped with lifelong medical complications, a losing war with their own bodies, and, tragically, sterilization.

Accordingly, it is the policy of the United States that it will not fund, sponsor, promote, assist, or support the so-called “transition” of a child from one sex to another, and it will rigorously enforce all laws that prohibit or limit these destructive and life-altering procedures.

Excellent.

The American medical establishment remains radically committed to the misnamed “gender-affirming care” model, refusing to even consider following the examples of the U.K., Sweden, Denmark, Finland, New Zealand, France, Norway, and others whose health ministries have hit the brakes hard on providing puberty blockers, hormones, and surgeries to gender dysphoric children.

Example: The current New England Journal of Medicine published a “Perspectives” screed attacking the Cass Review — widely respected for its thorough investigation of the lack of significant data supporting puberty blocking of gender dysphoric children. From “The Future of Gender Affirming Care“:

Our concern here is that the Review transgresses medical law, policy, and practice, which puts it at odds with all mainstream U.S. expert guidelines. The report deviates from pharmaceutical regulatory standards in the United Kingdom. And if it had been published in the United States, where it has been invoked frequently, it would have violated federal law because the authors failed to adhere to legal requirements protecting the integrity of the scientific process.